Author/Authors :
Narahara, Chisato Department of Clinical Product Development - Institute of Tropical Medicine - Nagasaki University, Nagasaki, Japan , Saeheng, Teerachat Department of Clinical Product Development - Institute of Tropical Medicine - Nagasaki University, Nagasaki, Japan , Chaijaroenkul, Wanna Chulabhorn International College of Medicine - Thammasat University, Pathumthani, Thailand , Dumre, Shyam Prakash Department of Immunogenetics - Institute of Tropical Medicine - Nagasaki University, Nagasaki, Japan , Na‑Bangchang, Kesara Chulabhorn International College of Medicine - Thammasat University, Pathumthani, Thailand , Karbwang, Juntra Department of Clinical Product Development - Institute of Tropical Medicine - Nagasaki University, Nagasaki, Japan
Abstract :
Background: Cholangiocarcinoma (CCA) is a neglected disease prevalent in developing countries with high burden and mortality
rate, and there is no effective treatment. We aimed to investigate β‑eudesmol molecular target of action in human CCA cell lines
using the selected key molecules of apoptotic pathways. Materials and Methods: Two CCA cell lines (HuH28 and HuCCT1) were
assessed at different time points after β‑eudesmol treatment for mRNA and protein expression profiles of caspase‑3, ‑8, ‑9, p53, p21,
Bcl‑2, and Bax by real‑time polymerase chain reaction and western blot, respectively. Results: β‑eudesmol induced expressions of
p21 and p53 in mRNA/protein level in HuH28 and HuCCT1 cells. These CCA cells also expressed caspase‑3, ‑8, ‑9 and bax (mRNA
and/or protein level) among others after β‑eudesmol treatment indicating its role in both intrinsic and extrinsic caspase‑dependent
apoptotic pathways. Conclusion: The study demonstrated that β‑eudesmol induced the expression of apoptosis pathway proteins,
suggesting its potential role in promoting the caspase‑dependent apoptotic pathway, and induction of the cell cycle arrest in CCA
cell lines. β‑eudesmol can be considered as a potential compound for further investigation as an anti‑CCA agent.
Keywords :
β‑eudesmol , molecular targets , mode of action , cholangiocarcinoma , Apoptosis
